MX2014008668A - Formulacion de pth estabilizada. - Google Patents

Formulacion de pth estabilizada.

Info

Publication number
MX2014008668A
MX2014008668A MX2014008668A MX2014008668A MX2014008668A MX 2014008668 A MX2014008668 A MX 2014008668A MX 2014008668 A MX2014008668 A MX 2014008668A MX 2014008668 A MX2014008668 A MX 2014008668A MX 2014008668 A MX2014008668 A MX 2014008668A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
formulation
hpth
lactate
parathyroid hormone
Prior art date
Application number
MX2014008668A
Other languages
English (en)
Spanish (es)
Inventor
Vaibhav Dnyaneshwar Deokar
Anjali Deepak Apte-Deshpande
Sheetal Arvind Raut
Balaji Damodaran
Cyrus Karkaria
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2014008668A publication Critical patent/MX2014008668A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014008668A 2012-01-20 2013-01-19 Formulacion de pth estabilizada. MX2014008668A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN53KO2012 2012-01-20
PCT/IB2013/050503 WO2013108235A1 (en) 2012-01-20 2013-01-19 Stabilized pth formulation

Publications (1)

Publication Number Publication Date
MX2014008668A true MX2014008668A (es) 2014-10-06

Family

ID=47714479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008668A MX2014008668A (es) 2012-01-20 2013-01-19 Formulacion de pth estabilizada.

Country Status (12)

Country Link
US (1) US20150011473A1 (show.php)
EP (1) EP2804622A1 (show.php)
JP (1) JP2015504087A (show.php)
AU (1) AU2013210689A1 (show.php)
BR (1) BR112014017424A8 (show.php)
CA (1) CA2862776A1 (show.php)
IN (1) IN2014MN01470A (show.php)
MX (1) MX2014008668A (show.php)
PH (1) PH12014501658A1 (show.php)
RU (1) RU2014133818A (show.php)
WO (1) WO2013108235A1 (show.php)
ZA (1) ZA201404918B (show.php)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3423103T3 (fi) 2016-03-01 2024-11-20 Ascendis Pharma Bone Diseases As PTH-aihiolääkkeitä
DK3518960T5 (da) 2016-09-29 2024-09-02 Ascendis Pharma Bone Diseases As Doseringsskema for en PTH-forbindelse med kontrolleret frigivelse
HRP20250102T1 (hr) 2016-09-29 2025-03-28 Ascendis Pharma Bone Diseases A/S Pth spojevi s kontroliranim oslobađanjem
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
JP6637220B2 (ja) * 2017-09-22 2020-01-29 旭化成ファーマ株式会社 薬物動態及び/又は安全性に優れるテリパラチド含有液状医薬組成物
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
JP2019156805A (ja) * 2018-03-16 2019-09-19 ナガセ医薬品株式会社 容器充填ヒトpth(1−34)液体医薬組成物及びその製造方法
WO2020028011A1 (en) * 2018-07-30 2020-02-06 Shire-Nps Pharmaceuticals Inc. Formulations for improved stability of recombinant human parathyroid hormone
KR20250171437A (ko) 2019-02-11 2025-12-08 아센디스 파마 본 디지즈 에이/에스 Pth 접합체의 액체 약학 제제
CN110917150A (zh) * 2019-12-31 2020-03-27 北京博康健基因科技有限公司 一种pth冻干制剂及其制备方法
WO2021195877A1 (en) * 2020-03-30 2021-10-07 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of human parathyroid hormone (pth) and methods for producing same
JP6947946B1 (ja) * 2020-05-11 2021-10-13 旭化成ファーマ株式会社 テリパラチド又はその塩を含有する安定な液状医薬製剤
WO2021229835A1 (ja) * 2020-05-11 2021-11-18 旭化成ファーマ株式会社 テリパラチド又はその塩を含有する安定な液状医薬製剤
TWI888383B (zh) * 2020-06-19 2025-07-01 丹麥商阿森迪斯藥物骨疾病股份有限公司 Pth綴合物的液體藥物製劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
JP4951344B2 (ja) * 2004-08-24 2012-06-13 第一三共株式会社 生理活性ペプチド液状製剤
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins

Also Published As

Publication number Publication date
JP2015504087A (ja) 2015-02-05
US20150011473A1 (en) 2015-01-08
CA2862776A1 (en) 2013-07-25
WO2013108235A1 (en) 2013-07-25
BR112014017424A2 (pt) 2017-06-13
AU2013210689A1 (en) 2014-07-31
ZA201404918B (en) 2016-01-27
IN2014MN01470A (show.php) 2015-04-17
EP2804622A1 (en) 2014-11-26
RU2014133818A (ru) 2016-03-20
BR112014017424A8 (pt) 2017-07-04
PH12014501658A1 (en) 2014-10-13

Similar Documents

Publication Publication Date Title
MX2014008668A (es) Formulacion de pth estabilizada.
JP7336482B2 (ja) 骨格異形成症を処置するためのc型ナトリウム利尿ペプチド変異体の使用
CN1198644C (zh) 人甲状旁腺激素药物组合物
RU2467762C2 (ru) Составы паратиреоидного гормона и их применение
CN102665691B (zh) hGH和rhIGF-1组合的制剂
RU2604809C2 (ru) Аналоги паратиреоидного гормона и их применение
EP3964522A1 (en) A method for extending half-life of a protein
KR20240035811A (ko) 소아의 골격 이형성증 치료를 위한 c-형 나트륨이뇨 펩티드 변이체
JP2021520365A (ja) インスリン化合物の送達のための医療用注入ポンプシステム
CN111989088A (zh) 用于递送胰岛素化合物的医用输注泵系统
US20220289812A1 (en) Elp fusion proteins comprising parathyroid hormone for controlled and sustained release
RU2794515C2 (ru) Применение вариантов натрийуретического пептида c-типа для лечения скелетной дисплазии
JP5300943B2 (ja) 骨形成を安全に促進させる医薬複合剤
WO2025141129A1 (en) Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses
HK1175711B (en) Formulation for hgh and rhigf-1 combination
MXPA06007761A (en) Methods and compositions for the treatment of lipodystrophy